Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT02809534 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

Start date: June 2016
Phase: Phase 2
Study type: Interventional

To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).

NCT ID: NCT02809287 Completed - Clinical trials for Hepatocellular Carcinoma

A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife Position

Start date: January 2015
Phase: N/A
Study type: Observational

Since the first report of laparoscopic resection of a benign hepatic tumor by Professor H. Reith in 1991, the laparoscope has been widely used in liver disease. Based on its advantages in laparoscopic vision and amplification, laparoscopic hepatectomy (LH) has been well recognized globally. Generally speaking, for lesions located in the left, front or lower part of the liver, corresponding to Couinaud segments II, III, IVb, V and VI, an LH surgery is recommended; however, for lesions located in segments VII and VIII, the surgery is high technically difficult due to poor exposure. Therefore,the investigators employ the left lateral position plus jackknife position to better expose lesions in these segments, hoping to reduce surgical time and bleeding in LH.

NCT ID: NCT02802124 Recruiting - Clinical trials for Hepatocellular Carcinoma

Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma

Start date: June 2016
Phase: Phase 1
Study type: Interventional

The aim of this research project is to assess the feasibility and safety of carbon-ion radiotherapy for the treatment of localized Chinese hepatocellular carcinoma

NCT ID: NCT02799212 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy

Start date: January 2017
Phase: Phase 3
Study type: Interventional

Most patients undergoing hepatectomy for hepatocellular carcinoma (HCC) suffer from underlying liver disease and are exposed to the risk of postoperative ascites, with subsequent morbidity, liver and renal failure, the need for specific treatments and prolonged hospital stay. Postoperative ascites is favored by an imbalance between portal venous inflow and the diminished hepatic venous outflow. Finding a reversible, non-invasive method for modulating the portal inflow would be of interest: it could be used temporarily during the early postoperative course to prevent acute portal hypertension. Somatostatin, a well-known drug already used in several indications, may limit the risk of postoperative ascites and liver failure by decreasing portal pressure after hepatectomy for HCC in patients with underlying liver disease.

NCT ID: NCT02785380 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Laparoscopic Surgery VS RFA for Recurrent HCC

Start date: December 2016
Phase: Phase 4
Study type: Interventional

Management of recurrent HCC is urgent and several treatments have been developed .Repeat hepatectomy is considered to be the first choice for recurrent HCC. Unfortunately, repeated open hepatectomy can be performed only in a small proportion of patients due to inadequate liver function reserve, widespread recurrence or high invasiveness. Given that recurrent tumors are usually detected at small size during follow-up after initial surgery, radiofreqency ablation (RFA), which is less invasive, may be locally curative and causes minimal damage to liver function reserve,has been widely used. However, the re-recurrence rate after RFA is more than 50%,and the recurrence-free survival is less than 20%. Recently, satisfactory short- and long-term oncological outcomes have been reported for laparoscopic surgery (LS) for the treatment for primary HCC with cirrhosis. Some single center pilot studies reported that LS may, compared with open surgery, improve the prognosis of HCC with less blood loss and shorter hospital stay. LS was initially considered not suitable for recurrent HCC due to postoperative adhesions that might make laparoscopic surgical procedure more difficult and less safe. With improvement in technique and experience, recent studies showed that LS for recurrent HCC in cirrhotic patients is a safe and feasible procedure with good short-term outcomes. However, thus far, no study has been performed to evaluate the long-term oncological outcomes of LS for recurrent HCC, and compare those results to that for RFA. To clarify these issues, a multicenter retrospective comparative study by using propensity score matching method that included a large consecutive series of patients with recurrent HCC within Milan criteria, who underwent LS or RFA, was performed.

NCT ID: NCT02783261 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Post Y90 Liver Hypertrophy

Start date: June 2014
Phase: N/A
Study type: Observational

Patients undergoing Y90 radioembolization to will be followed prospectively with CT volumetry to determine post-Y90 rate of liver hypertrophy.

NCT ID: NCT02772029 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Start date: May 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Hepatocellular carcinoma (HCC) is one of the lethal human cancers worldwide and its incidence matches mortality, reflecting the poor prognosis of this disease. The surgical resection rate of HCC is low, and the prognosis is poor. Although transarterial chemoembolization (TACE) is the main treatment for HCC patients who are not candidates for surgical resection, it is not considered a curative procedure. For HCC, poor TACE efficacy or TACE failure may be related to tumor angiogenesis of the residual disease. Among the many regulatory factors in tumor angiogenesis, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) play vital roles in this process. Sorafenib is the first systemic treatment drug, which has been approved by the FDA for advanced HCC. In order to find an new VEGFR-inhibitor with better effect and lower toxicity, Jiangsu Hengrui Medicine Co., Ltd. developed Apatinib, a high-performance VEGFR-2 tyrosine kinase inhibitor. Apatinib plays anti angiogenic effect in the treatment of malignant tumor mainly through inhibition of VEGFR-2, in vivo and in vitro experiments showed good tumor growth inhibitory activity on glioma, this study aims to further verify the efficacy and safety of Apatinib for first-line treatment failure hepatocellular carcinoma patients, the primary endpoint is time to progression(TTP).

NCT ID: NCT02771405 Recruiting - Clinical trials for Hepatocellular Carcinoma

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

Start date: March 2016
Phase: Phase 3
Study type: Interventional

The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.

NCT ID: NCT02767375 Recruiting - Clinical trials for Hepatocellular Carcinoma

Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection

Start date: February 2015
Phase: Phase 2/Phase 3
Study type: Interventional

To study if the addition of HAIC following complete removal of early stage liver cancer of HCC will prevent or delay the recurrence of the disease. Half of the participant will receive two cycles of the HAIC after the hepatectomy, while the other half will return to the baseline surveillance schedule.

NCT ID: NCT02759601 Recruiting - Clinical trials for Hepatocellular Carcinoma

Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being carried out to assess the best dose of a new drug, called tefinostat, in treating liver cancer. Tefinostat is a new drug that blocks enzymes called histone deacetylases (pronounced dee-as-et-isle-azes). Cells need these enzymes to grow and divide. Blocking them may stop cancer growing. Drugs that block these enzymes are called histone deacetylase inhibitors or 'HDAC inhibitors'. Tefinostat has never been given to patients with liver cancer before so we don't know which dose is best at treating liver cancer. To find this out we will be testing one dose and if that is safe we will then test a higher dose and so on. Eventually we will find the best dose; we do not know when this will be. When we find the best dose we will treat another 39 patients with this dose. The aim of this study is to find the best dose of tefinostat without causing side effects. We will be looking closely at any side effects you might experience from this treatment.